Clinical Trials Logo

Filter by:
  • Withdrawn  
  • « Prev · Page [2]
NCT ID: NCT01787773 Withdrawn - Clinical trials for Deep Vein Thrombosis

VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism

VERITAS
Start date: March 2013
Phase: N/A
Study type: Interventional

This is a prospective, multicenter single arm, nonrandomized study that will include 150 patients at a maximum of 20 investigational sites. It is estimated that it may take 13 months to complete enrollment. Follow-up will continue through 24 months post-implant or one month post-retrieval, whichever occurs first. It is required that filters be retrieved from at least 50 patients and the filter is permanent in at least 50 patients.

NCT ID: NCT01624493 Withdrawn - Ovarian Cancer Clinical Trials

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.

NCT ID: NCT01266811 Withdrawn - Multiple Myeloma Clinical Trials

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Start date: July 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is added to VELCADE and dexamethasone in subjects with relapsed or refractory multiple myeloma.

NCT ID: NCT00168051 Withdrawn - Hemophilia A Clinical Trials

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Start date: April 2005
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.